Commentary
Podcast
Author(s):
The COBBRA trial compared bleeding risk with rivaroxaban versus apixaban in patients with acute venous thromboembolism.
This week, host Craig Beavers sat down with Tara Lech, PharmD, CACP, director of anticoagulation services at Beth Israel Lahey Health, to discuss recent findings from the COBBRA trial, which compared bleeding risk with rivaroxaban versus apixaban in patients with acute venous thromboembolism.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.